Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Turnstone Biologics Inc.

www.turnstonebio.com

Latest From Turnstone Biologics Inc.

Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma

Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.

Appointments BioPharmaceutical

AbbVie Expects 9% Tax Rate, Thanks To US Tax Reform Law

The tax reform windfall makes an already strong fourth quarter and full year 2017 financial report more impressive for AbbVie, which reported continuing growth for Humira and Imbruvica, and a big uptick in HCV.

Sales & Earnings Business Strategies

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

Deal Watch: AbbVie Bets On Turnstone’s Cancer Immunotherapy Technology

AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Turnstone Biologics Inc.
  • Senior Management
  • Sammy Farah, PhD, Pres. & CEO
    Brian Lichty, PhD, SVP, Basic Rsch.
    Kris Elverum, CBO
  • Contact Info
  • Turnstone Biologics Inc.
    Phone: (613) 421-8930
    787 Bank St.
    2nd Fl.
    Toronto, K1S 3V5
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register